Processa Pharmaceuticals Stock Performance
| PCSA Stock | USD 2.88 0.05 1.71% |
On a scale of 0 to 100, Processa Pharmaceuticals holds a performance score of 2. The company holds a Beta of -0.43, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Processa Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Processa Pharmaceuticals is likely to outperform the market. Please check Processa Pharmaceuticals' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Processa Pharmaceuticals' historical price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Processa Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Processa Pharmaceuticals sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.71) | Five Day Return (17.00) | Year To Date Return (87.21) | Ten Year Return (99.79) | All Time Return (99.97) |
Last Split Factor 1:25 | Dividend Date 2019-12-23 | Last Split Date 2025-12-17 |
1 | Should you wait for a breakout in Processa Pharmaceuticals Inc. - Trade Entry Report Step-by-Step Swing Trade Plans - newser.com | 10/16/2025 |
2 | Will Processa Pharmaceuticals Inc. stock sustain high P E ratios - July 2025 Retail Short-Term Trading Alerts - newser.com | 10/31/2025 |
3 | Will Processa Pharmaceuticals Inc. stock benefit from infrastructure spending - July 2025 Momentum Weekly Breakout Stock Alerts - newser.com | 11/04/2025 |
4 | Acquisition by Patrick Lin of 3 shares of Processa Pharmaceuticals subject to Rule 16b-3 | 11/12/2025 |
5 | Maxim Group Maintains Processa Pharmaceuticals With Hold Rating - | 11/20/2025 |
6 | Acquisition by Neal James R of 300000 shares of Processa Pharmaceuticals at 0.198 subject to Rule 16b-3 | 12/10/2025 |
7 | Processa Pharmaceuticals to effect 1-for-25 reverse stock split - marketscreener.com | 12/15/2025 |
8 | PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study | 12/18/2025 |
9 | Acquisition by Wendy Guy of 150000 shares of Processa Pharmaceuticals at 0.198 subject to Rule 16b-3 | 12/30/2025 |
| Begin Period Cash Flow | 4.7 M | |
| Total Cashflows From Investing Activities | -3244.00 |
Processa Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 533.00 in Processa Pharmaceuticals on October 3, 2025 and sell it today you would lose (245.00) from holding Processa Pharmaceuticals or give up 45.97% of portfolio value over 90 days. Processa Pharmaceuticals is currently generating 0.6831% in daily expected returns and assumes 20.5947% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Processa, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Processa Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Processa Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Processa Pharmaceuticals, and traders can use it to determine the average amount a Processa Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0332
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PCSA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Processa Pharmaceuticals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Processa Pharmaceuticals by adding it to a well-diversified portfolio.
Processa Pharmaceuticals Fundamentals Growth
Processa Stock prices reflect investors' perceptions of the future prospects and financial health of Processa Pharmaceuticals, and Processa Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Processa Stock performance.
| Return On Equity | -2.71 | ||||
| Return On Asset | -1.3 | ||||
| Current Valuation | 330.28 K | ||||
| Shares Outstanding | 2.27 M | ||||
| Price To Book | 1.14 X | ||||
| EBITDA | (12.05 M) | ||||
| Net Income | (11.85 M) | ||||
| Cash And Equivalents | 12.06 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 73.51 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 8.89 X | ||||
| Book Value Per Share | 2.76 X | ||||
| Cash Flow From Operations | (11.25 M) | ||||
| Earnings Per Share | (28.75) X | ||||
| Market Capitalization | 6.64 M | ||||
| Total Asset | 3.23 M | ||||
| Retained Earnings | (87.22 M) | ||||
| Working Capital | 340.99 K | ||||
About Processa Pharmaceuticals Performance
By analyzing Processa Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Processa Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Processa Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Processa Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 635.83 | 342.18 | |
| Return On Tangible Assets | (3.67) | (3.85) | |
| Return On Capital Employed | (7.10) | (6.75) | |
| Return On Assets | (3.67) | (3.85) | |
| Return On Equity | (6.99) | (6.64) |
Things to note about Processa Pharmaceuticals performance evaluation
Checking the ongoing alerts about Processa Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Processa Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Processa Pharmaceuticals is way too risky over 90 days horizon | |
| Processa Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Processa Pharmaceuticalshas 3,454,719 shares shorted by Processa Pharmaceuticals investors is about 100% of outstending shares | |
| Net Loss for the year was (11.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Processa Pharmaceuticals currently holds about 12.06 M in cash with (11.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Processa Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to 236 Million |
- Analyzing Processa Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Processa Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Processa Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Processa Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Processa Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Processa Pharmaceuticals' stock. These opinions can provide insight into Processa Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Processa Stock analysis
When running Processa Pharmaceuticals' price analysis, check to measure Processa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Processa Pharmaceuticals is operating at the current time. Most of Processa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Processa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Processa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Processa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |